All News
Krill Oil Effective in Knee Osteoarthritis
Krill oil supplements in knee osteoarthritis (OA) was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index.
Read Article
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.
Read Article
Upadacitinib in non-radiographic Axial Spondyloarthritis
The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.
Read Article
"He who has a strong enough why; can bear almost any how"
- Friedrich Nietzsche https://t.co/BOpO9MMijR
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthritis - 15 mg qd p.o. Approval based on Phase 3 SELECT-AXIS 2 nr-axSpA trial published in Lancet https://t.co/n3Pci5GyoA https://t.co/4aoSOc7xHd
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic- Still's (or Not): Fever, Joint pain & Itchy Eyes
30 yr. woman with high fevers, itchy eyes and Still's manifestations for 6 weeks.
Still's or Not?
https://t.co/kbzhCxYp7H https://t.co/FEUzdXxHoW
Links:
Dr. John Cush RheumNow ( View Tweet)
Not Still’s – Now What?
Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?
https://t.co/xPXZVzTXJr https://t.co/7hmhXFh6O3
Links:
Dr. John Cush RheumNow ( View Tweet)
Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
https://t.co/MLBGL2ZqTk https://t.co/cdO2nHAK6h
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
https://t.co/2tlibH3SHO https://t.co/QsmkfeGEvb
Links:
Dr. John Cush RheumNow ( View Tweet)
Physician Assistant Salaries -Amer Academy of Physician Assoc 2022 Report
Critical care $122,832
Emer Med $121,480
Surgery $121,400
Cardiology $118,000
Heme/Onc $117,297
Rheumatology $113,000
ID $113,000
GI $113,000
Pulm $112,900
PCP $112,000
https://t.co/14SafbtTGm https://t.co/1yuPI5pAYE
Links:
Dr. John Cush RheumNow ( View Tweet)
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc
Dr. John Cush RheumNow ( View Tweet)
THe microbiome differs between #AS (n 33) and AS-IBD(59) compared to IBD (105) patients. Study comparing feces & intesting Bx. Microbiome composition correlated with BASDAI and faecal calprotectin (FCP) levels. https://t.co/D4QCVVDK7G https://t.co/OJkeisycg0
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of Clinical Trial measures in systemic sclerosis:
-RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk
-FVC is surrogate measure for SSc-ILD
- Composites: CRISS, the EUSTAR-AI
-Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/KPLiNTSSZA https://t.co/YgvWuMiU4i
Dr. John Cush RheumNow ( View Tweet)
Heterozygous deficiency of Aggrecan (proteoglycan w/in cartilage) gene: manifests as inherited short stature, early-onset osteoarthritis, degenerative disc disease, osteochondritis dissecans, increasing joint pathology over time https://t.co/dQERowhrba https://t.co/q7a38FGEzb https://t.co/TPQmnGPoDw
Dr. John Cush RheumNow ( View Tweet)
Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/TKyNDwIUQH https://t.co/6VaMOMfwYi
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/hksDaCSj02 https://t.co/eGRVqZiBBx
Links:
Dr. John Cush RheumNow ( View Tweet)
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
https://t.co/5M92Yhpeo1 https://t.co/qZvwfLs1jx
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/CbRQGzxJEr https://t.co/SlJNprUay3
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast—Dr.Cush answers your questions!
https://t.co/cif6yo0tGi https://t.co/kia5J0OMf6
Links:
Dr. John Cush RheumNow ( View Tweet)